MaaT Pharma was informed of a negative trend during the Committee for Medicinal Products for Human Use (CHMP)’s Oral Explanation meeting which ...
Elixir Medical (Milpitas, Calif., and Tokyo) announced that its DynamX® Sirolimus-Eluting Coronary Bioadaptor System for the treatment of cor...
Icosagen's IcoCell® platform delivered a high-titer, stable CHO cell line for a precision engineered therapeutic antibody-like protein, providing the f...
Sygnature Discovery, a leading integrated drug discovery contract research organisation (CRO), has established a formal collaboration with X-Chem, a data...
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bac...
All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injecti...
Cellectis to advance two lead in vivo programs .HEAL-101 and .HEAL-201 in severe dyslipidemias with preliminary Phase 1 data planned in H2 2027 and H1 ...
Novo Nordisk marked the beginning of its next chapter today by unveiling a rebrand centred on ‘Lasting Health Starts Now’, and the single &ls...
HOPE is the first Interventional Psychiatry network to deploy Zeta Surgical's newly FDA-cleared TMS Robotic System; the HOPE clinical team is completin...
Omniscient announced 510(k) clearance from the U.S. Food and Drug Administration for a new workflow within the Quicktome® platform: Quicktome Deep Br...
Tambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase III study conducted in China, reducing the ri...
Approximately 600 patients expected to be enrolled at clinical sites across the United States, Europe, China and South America Global Phase 3 program, R...
Insilico Medicine ("Insilico," HKEX: 3696), a clinical-stage biotechnology company powered by generative AI, announced that it has dosed the first patien...
Detailed Phase 3 CANOPY-HCH-3 data in children living with hypochondroplasia also featured in a late-breaking oral presentation at th...
© 2026 Biopharma Boardroom. All Rights Reserved.
